World Journal of
Pharmaceutical and Life Sciences

LC–MS EVALUATION OF VINLEUROSINE AND ITS ANTINEOPLASTIC EFFICACY IN EYE CANCER CELL LINE MODELS

Somabatthini Shruthi*, Dr. Syed Ahmed Hussain, Ghousia Begum, Nada Ahmed Al Amoodi, Fariya Sultana, Bilquis Begum, Ayesha Ayub Khan, Muskan Khatoon

ABSTRACT

This study evaluates the in vitro cytotoxic and antiproliferative potential of Vinleurosine compared to Vinblastine in eye cancer cell line models, including retinoblastoma (Y79, WERI-Rb1) and uveal melanoma (OCM-1, 92.1). A five-assay panel was implemented, encompassing two viability assays (Resazurin/Alamar Blue and ATP Luminescence) and three cytotoxicity assays (Annexin V/PI, Caspase-3/7 activity, and LDH release). Vinleurosine demonstrated a profound reduction in cell viability (34% and 30%) compared to Vinblastine (100% in both), indicating strong antiproliferative activity. It also induced extensive apoptosis (65%), 4.3-fold caspase activation, and 71% LDH release, signifying robust apoptotic and late cytolytic events. In contrast, Vinblastine displayed negligible cytotoxicity (7% apoptosis, 1.0-fold caspase activation, 8% LDH). These findings confirm Vinleurosine’s potent pro-apoptotic and cytotoxic behavior through caspase-dependent mechanisms. Collectively, Vinleurosine demonstrates a superior therapeutic profile against ocular tumor cells, suggesting its potential as a promising candidate for advanced eye cancer chemotherapy.

[Full Text Article]   [Download Certificate]